+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Friedreich Ataxia (Central Nervous System) - Drugs In Development, 2021

  • ID: 5402689
  • Report
  • July 2021
  • Region: Global
  • 172 Pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • AavantiBio Inc
  • Biovista Inc
  • Epirium Bio Inc
  • Healx Ltd
  • Larimar Therapeutics Inc
  • Novartis Gene Therapies
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Drugs In Development, 2021, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 3, 21, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AavantiBio Inc
  • Biovista Inc
  • Epirium Bio Inc
  • Healx Ltd
  • Larimar Therapeutics Inc
  • Novartis Gene Therapies
Introduction
Friedreich Ataxia - Overview
  • Friedreich Ataxia - Therapeutics Development
Friedreich Ataxia - Therapeutics Assessment
Friedreich Ataxia - Companies Involved in Therapeutics Development
Friedreich Ataxia - Drug Profiles
Friedreich Ataxia - Dormant Projects
Friedreich Ataxia - Discontinued Products
Friedreich Ataxia - Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Friedreich Ataxia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Friedreich Ataxia - Pipeline by AavantiBio Inc, 2021
  • Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, 2021
  • Friedreich Ataxia - Pipeline by Amylyx Pharmaceuticals Inc, 2021
  • Friedreich Ataxia - Pipeline by Anima Biotech Inc, 2021
  • Friedreich Ataxia - Pipeline by Biointaxis SL, 2021
  • Friedreich Ataxia - Pipeline by Biovista Inc, 2021
  • Friedreich Ataxia - Pipeline by Cellivery Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by CRISPR Therapeutics AG, 2021
  • Friedreich Ataxia - Pipeline by Design Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by Epirium Bio Inc, 2021
  • Friedreich Ataxia - Pipeline by Exicure Inc, 2021
  • Friedreich Ataxia - Pipeline by Fratagene Therapeutics Srl, 2021
  • Friedreich Ataxia - Pipeline by Fulcrum Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by Healx Ltd, 2021
  • Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, 2021
  • Friedreich Ataxia - Pipeline by Jupiter Orphan Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by Lacerta Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by Larimar Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by LEXEO Therapeutics LLC, 2021
  • Friedreich Ataxia - Pipeline by Metro International Biotech LLC, 2021
  • Friedreich Ataxia - Pipeline by Minoryx Therapeutics sl, 2021
  • Friedreich Ataxia - Pipeline by Novartis Gene Therapies, 2021
  • Friedreich Ataxia - Pipeline by PTC Therapeutics Inc, 2021
  • Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, 2021
  • Friedreich Ataxia - Pipeline by Retrotope Inc, 2021
  • Friedreich Ataxia - Pipeline by Seelos Therapeutics, Inc., 2021
  • Friedreich Ataxia - Pipeline by STATegics Inc, 2021
  • Friedreich Ataxia - Pipeline by Stealth BioTherapeutics Corp, 2021
  • Friedreich Ataxia - Pipeline by StrideBio Inc, 2021
  • Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, 2021
  • Friedreich Ataxia - Dormant Projects, 2021
  • Friedreich Ataxia - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Friedreich Ataxia, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AavantiBio Inc
  • Adverum Biotechnologies Inc
  • Amylyx Pharmaceuticals Inc
  • Anima Biotech Inc
  • Biointaxis SL
  • Biovista Inc
  • Cellivery Therapeutics Inc
  • CRISPR Therapeutics AG
  • Design Therapeutics Inc
  • Epirium Bio Inc
  • Exicure Inc
  • Fratagene Therapeutics Srl
  • Fulcrum Therapeutics Inc
  • Healx Ltd
  • Ixchel Pharma LLC
  • Jupiter Orphan Therapeutics Inc
  • Lacerta Therapeutics Inc
  • Larimar Therapeutics Inc
  • LEXEO Therapeutics LLC
  • Metro International Biotech LLC
  • Minoryx Therapeutics sl
  • Novartis Gene Therapies
  • PTC Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • Retrotope Inc
  • Seelos Therapeutics, Inc.
  • STATegics Inc
  • Stealth BioTherapeutics Corp
  • StrideBio Inc
  • Voyager Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll